Literature DB >> 23707855

High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients.

Michael D Chuong1, Daniel C Fernandez, Ravi Shridhar, Sarah E Hoffe, Amarjit Saini, Dylan Hunt, Kenneth L Meredith, Matthew C Biagioli.   

Abstract

PURPOSE: Preoperative high-dose-rate (HDR) endorectal brachytherapy is well tolerated among patients with locally advanced rectal cancer. However, these studies excluded patients who previously received pelvic radiation therapy (RT). Because a favorable toxicity profile has been published for HDR endorectal brachytherapy, we evaluated this technique in patients who have previously received pelvic irradiation. METHODS AND MATERIALS: We included patients who had received pelvic irradiation for a previous pelvic malignancy and later received preoperative HDR endorectal brachytherapy for rectal cancer. Brachytherapy was delivered to a total dose of 26 Gy in 4 consecutive daily 6.5 Gy fractions.
RESULTS: We evaluated 10 patients who previously received pelvic external beam radiation therapy (EBRT) alone (n=6), EBRT and brachytherapy (n=2), or brachytherapy alone (n=2). The median interval between the initial course of RT and endorectal brachytherapy was approximately 11 years (range, 1-19 years). Two patients experienced a complete pathologic response while 1 patient had a near complete pathologic response. No acute grade ≥3 toxicity was observed. No intraoperative or postoperative surgical complications were observed.
CONCLUSIONS: Preoperative HDR endorectal brachytherapy is an alternative to EBRT for patients with locally advanced rectal cancer who have previously received pelvic RT.
Copyright © 2013 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endorectal brachytherapy; High-dose-rate; Rectal cancer; Reirradiation

Mesh:

Year:  2013        PMID: 23707855     DOI: 10.1016/j.brachy.2012.11.003

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  2 in total

1.  Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapy.

Authors:  Shalini Moningi; Amanda J Walker; Ashkan A Malayeri; Lauren M Rosati; Susan L Gearhart; Jonathan E Efron; Elizabeth C Wick; Nilofer S Azad; Elwood P Armour; Yi Le; Joseph M Herman; Eun Ji Shin
Journal:  Gastrointest Endosc       Date:  2015-03       Impact factor: 9.427

2.  Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies.

Authors:  Shalini Moningi; Ethan B Ludmir; Praveen Polamraju; Tyler Williamson; Marcella M Melkun; Joseph D Herman; Sunil Krishnan; Eugene J Koay; Albert C Koong; Bruce D Minsky; Grace L Smith; Cullen Taniguchi; Prajnan Das; Emma B Holliday
Journal:  Clin Transl Radiat Oncol       Date:  2019-08-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.